

Atty. Docket No.: 8654/2002

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of Eberhard Amtmann et al.

Examiner: Cook, Rebecca

Serial No.: 09/784,618

Filed: February 15, 2001

Group Art Unit: 1614

Entitled: "Medicament Containing Platinum Complex Compounds and the Use Thereof"

Conf. No.: 2652

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

Elizabeth N. Spar

Name of Person Mailing Paper

Signature of Person Mailing Paper

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56, 1.97 AND 1.98

Dear Sir:

In accordance with the duty of disclosure under 37 CFR § 1.56, Applicant submits this Supplemental Information Disclosure Statement pursuant to 37 CFR §§ 1.97 and 1.98 in the above-identified application for consideration by the Patent Office. A listing of the cited documents is also enclosed, as well as, for the Examiner's convenience, copies of the documents in the list.

Applicants do not intend to represent that any of the documents submitted herein are material prior art to this invention or that the list represents an exhaustive search of documents related to this invention.

Applicants respectfully request that the documents submitted herein be considered and made of record in this application.

Pursuant to CFR § 1.97(c)(2), because this Statement is being submitted after the mailing of the Final Office Action on the merits, authorization to charge the requisite fee of \$180.00 to Deposit Account 16-0085, Ref. 8654/2002 can be found on the transmittal letter accompanying this submission. Pursuant to CFR § 1.97(e)(1) Applicants submit that each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

Date: 12/16/03

Respectfully submitted,

Name: Kathleen M. Williams

Registration No.: 34,380


Customer No.: 29933

Palmer & Dodge LLP

111 Huntington Avenue

Boston, MA 02199-7613

Tel: 617-239-0100



USPTO Form 1449 Patent and Trademark Office Department of Commerce				Attorney Docket No. 8654/2002		Serial No. 09/784,618		
INFORMATION DISCLOSURE STATEMENT				Applicant(s): Eberhard Amtmann et al.				
				Filing Date: February 15, 2001		Group: 1614		
U.S. PATENT DOCUMENTS								
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)	
FOREIGN PATENT DOCUMENTS								
Examiner Initial		Document No.	Publication Date	Country	Class	Subclass	Translation	
							YES	NO
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)								
	1.	Kharkyevitch, D. A., (1987), <i>The dependence of the pharmacotherapeutic effect on the properties of pharmaceuticals and on their application conditions</i> . Medicine (Moscow) pp. 47 - 48 [English Translation of original Russian article].						
EXAMINER				DATE CONSIDERED				
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</small>								
<small>**Copies of references not provided at the time of this submission.</small>								